Dexcom Promotes Jacob S. Leach to President and COO

Dexcom ( (DXCM) ) has shared an update.

On May 9, 2025, Dexcom announced the promotion of Jacob S. Leach to President and Chief Operating Officer, effective immediately. Leach, who has been with the company for over 21 years, will now oversee corporate development and strategy efforts in addition to his existing responsibilities. This move is expected to strengthen Dexcom’s ability to innovate and achieve its goals in the metabolic health sector, benefiting customers, shareholders, and communities.

The most recent analyst rating on (DXCM) stock is a Buy with a $132.00 price target. To see the full list of analyst forecasts on Dexcom stock, see the DXCM Stock Forecast page.

Spark’s Take on DXCM Stock

According to Spark, TipRanks’ AI Analyst, DXCM is a Outperform.

Dexcom’s overall stock score reflects its strong financial performance and positive technical analysis signals, despite valuation concerns and operational challenges. The earnings call and recent corporate events indicate strategic growth initiatives, while the high P/E ratio and absence of a dividend yield remain key considerations for potential investors.

To see Spark’s full report on DXCM stock, click here.

More about Dexcom

Dexcom, founded in 1999, is a leader in real-time continuous glucose biosensing technology, which has revolutionized diabetes management and glucose tracking, empowering individuals to take control of their health.

Average Trading Volume: 4,627,534

Technical Sentiment Signal: Hold

Current Market Cap: $33.35B

See more insights into DXCM stock on TipRanks’ Stock Analysis page.